The growth in this market is mainly driven by the shift from standalone to hybrid modalities, advances in radiotracers, the increasing focus on personalized medicine, investments through public-private partnerships to modernize diagnostic imaging centers, and the increasing incidence and prevalence of cancer and cardiac ailments.
The report Nuclear Imaging Equipment Market is expected to reach USD 3.4 billion by 2025 from USD 2.6 billion in 2020, at a CAGR of 4.9% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=98 Market Segmentation: - By product, the SPECT imaging systems segment is expected to account for the largest share of the Nuclear Imaging Equipment market in 2020 Based on product, the nuclear imaging equipment market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems. The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems. The SPECT imaging systems segment is expected to the largest share in 2019. The large share of this segment can be attributed to high adoption of SPECT imaing systems on account of lower cost as compared to hybrid PET imaging systems, By application, the oncology segment is expected to account for the largest share of the nuclear imaging equipment market in 2020 Based on application, the nuclear imaging equipment market is segmented into oncology, cardiology, neurology, and other applications. The oncology application segment is expected to register the highest CAGR during the forecast period. The major factors contributing to the growth of this segment include the rising incidence and prevalence of cancer across the globe, initiatives taken by public and private organizations to curb the rising cancer prevalence, and the development of advanced systems and radiotracers for oncology. By end-user, the hospitals end-user segment is expected to account for the largest share of the Nuclear Imaging Equipment market in 2020 Based on end user, the nuclear imaging equipment market is segmented into hospitals, imaging centers, academic & research centers, and other end users. Hospitals accounted for the largest share of the global nuclear imaging equipment market in 2019. This can be attributed to factors such as the need to improve the efficiency of diagnostic imaging procedures and the rising number of diagnostic imaging procedures performed in hospitals. Regional Analysis: - North America to dominate the market in 2020 North America, Europe, Asia Pacific, and the Rest of the World (RoW) are the regions considered for geographic analysis of the global nuclear imaging equipment market study. North America is expected to account for the largest share of the global nuclear imaging equipment market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=98 Key Market Players: - The prominent players in the global nuclear imaging equipment market include are Siemens Healthineers (Germany), Philips Healthcare (Netherlands), and GE Healthcare (US). The other players in the market include Toshiba Medical Systems Corporation (Japan), Neusoft Medical Systems Co., Ltd. (China), Mediso Medical Imaging Systems Ltd. (Hungary), Digirad Corporation (US), CMR Naviscan Corporation (US), SurgicEye GmbH (Germany), and DDD Diagnostics (Denmark).
0 Comments
Revenue Cycle Management (RCM) in healthcare industry has fast become a buzzword over the past few years. It enables the healthcare organizations to manage payments, claims processing, and revenue generation, thereby accelerating the whole revenue cycle in an efficient manner. RCM solution begins when a patient enters or schedules an appointment. It automates the whole procedure with initiation of the process by the patient, quick follow ups, determining the eligibility of the patient, collecting their payment, effective tracking of the claims process, and working on rejected claims among others. The rising need for streamlining the whole process has further boosted the demand for RCM solutions, thereby triggering the growth of the RCM market. The Revenue Cycle Management Market is expected to reach USD 160.08 billion by 2027 from USD 66.81 billion in 2019, at a CAGR of 12.1%. Request for Sample Pages: – https://www.marketsandmarkets.com/requestsampleNew.asp?id=153900104 On the basis of function, the market is broadly segmented into claim and denial management, medical billing and coding, patient insurance eligibility check, payment remittance, electronic health record (EHR), clinical documentation improvement (CDI), and others. The claim and denial management segment is expected to account for the largest share of the global Revenue Cycle Management Industry in 2017 and is expected to witness the highest CAGR during the forecast period. The growing demand for claims and denial management due to the dynamic reimbursement structure and the increasing instances of claim denials are the major factors driving the growth of this segment. What’s driving the Market? The growth of the global revenue cycle management market is primarily propelled by the following factors:
Ask for PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153900104 The key players in the global Revenue Cycle Management Industry are McKesson (US), Cerner (US), Quest Diagnostics (US), Allscripts Health Solutions (US), and athenahealth (US). The global mycoplasma testing markets growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.
The global Mycoplasma Testing Market size is projected to reach USD 1,095 million by 2025 from USD 689 million in 2020, at a CAGR of 9.7%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856 Market Segmentation: - The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this markets largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the essential factors driving this market segments growth. Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segments growth. Regional Analysis:- The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global mycoplasma testing market. The large share can be attributed primarily to the growth in biotechnology and pharmaceutical industries, the high adoption rate of novel technologies, and the large number of life science research studies conducted in this region. Recent Developments
Request for sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=136509856 Top Key Players: - The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US) and Bionique Testing Laboratories, Inc. (US). Major factors driving the market growth are increasing prevalence of respiratory diseases, growing geriatric population, and technological advancements in respiratory diagnostic systems. On the other hand, rising healthcare costs and reimbursement concerns are the major factors restraining the growth of the respiratory diagnostics market. High potential emerging markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore offer significant growth opportunities for the key players in the respiratory diagnostics market.
The global Respiratory Diagnostics Market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163390459 The global respiratory diagnostics market is segmented on the basis of product and service, test type, disease, end user, and region. On the basis of product and service, the respiratory diagnostics market is segmented into instruments and devices, assays and reagents, and software and services. The instruments and devices segment is expected to account for the largest share of the respiratory diagnostics market in 2016. On the basis of test type, the respiratory diagnostics market is broadly classified into mechanical tests, imaging tests, traditional diagnostic tests, and molecular diagnostic tests. In 2016, the traditional diagnostic tests segment is expected to account for the largest share of the respiratory diagnostics market. On the basis of disease, the respiratory diagnostics market is segmented into asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis, and other diseases. The tuberculosis segment is expected to account for the largest share of the respiratory diagnostics market in 2016. On the basis of end user, the respiratory diagnostics market is categorized into hospital/clinical laboratories, reference laboratories, physician offices, and other end users (including blood banks, point-of-care testing, patient self-testing, home health agencies, nursing homes, and local public health laboratories). North America is expected to account for the largest share of the global respiratory diagnostics market in 2016, followed by Europe. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=163390459 The respiratory diagnostics market is dominated by established players such as Philips Healthcare (Netherlands), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Alere, Inc. (U.S.). The growth in this market is majorly driven by the growth in the companion animal population, rising demand for pet insurance and growing animal health expenditure, growing number of veterinary practitioners & their rising income levels in developed economies, rising demand for animal-derived food products, and growing prevalence of animal diseases. However, high cost of veterinary imaging instruments and rising pet care costs are expected to restrain the growth of this market.
The report Veterinary Imaging Market is projected to reach USD 2.2 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Ask for PDF Brochure :-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80889726 Market Segmentation: - Based on product, the veterinary imaging market is segmented into instrument, reagents, and software. The instruments segment accounted for the largest market share in 2019. The large share of this segment can be attributed to the high cost of imaging instruments and the increasing adoption of imaging modalities for disease diagnosis in the treatment of companion animals and livestock. On the basis of animal type, the veterinary imaging market is segmented into small companion animals, large animals, and other animals. The small companion animal segment accounted for the largest share of the market in 2019. The large share and highest growth of this segment is attributed to the growing pet adoption due to rising urbanization, growing expenditure on pet care, increasing demand for pet insurance, the growing adoption of animal-assisted therapy, economic growth, and the rising incidence of age-related diseases in companion animals. Based on end users, the veterinary imaging market is segmented into veterinary clinics and diagnostic centers and veterinary hospitals and academic institutions. Veterinary clinics and diagnostic centers accounted for the largest share of the market in 2019. The large share of this segment is attributed to the increasing number of veterinarians and the growing number of private clinical practices across the globe. Regional Analysis: - The veterinary imaging market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latina America, and the Middle East and Africa. In 2019, North America accounted for the largest share. The large share of North America can be attributed to the increasing population of companion animals, rising veterinary healthcare expenditure, the growing population of livestock due to the increasing consumption of meat and dairy products, and growth in pet insurance coverage. Request for Sample Pages :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=80889726 Top key players: - Some of the prominent players in this market are GE Healthcare (US), Agfa-Gevaert N.V. (Belgium), Carestream Health, Inc. (US), Esaote S.p.A (Italy), IDEXX Laboratories, Inc. (US), Mindray Medical International Limited (China), Canon Inc. (Japan), Heska Corporation (US), Siemens Healthineers (Germany), FUJIFILM Holdings Corporation (Japan), Konica Minolta (Japan), Samsung Electronics Co. Ltd. (South Korea), E.I. Medical Imaging (US), IMV imaging (UK), SEDECAL (Spain), Clarius Mobile Health (Canada), Shenzhen Ricso Technology Co., Ltd. (China), DRAMIÑSKI S.A. (Poland), EPICA Animal Health (US), and ClearVet Digital Radiography Systems (US). The major factors driving the growth of the laboratory balances and scales market are the technological advancements in laboratory balances and scales; increasing research investments and activities among pharma-biotech companies and CROs; increasingly stringent regulatory framework for product safety in bio-pharmaceutical industries; implementation of stringent food safety guidelines; and emerging markets.
The global Laboratory Balances and Scales Market is projected to reach USD 1.6 billion by 2023 from USD 1.3 billion in 2018, at a CAGR of 3.7%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=166668097 The analytical balances segment is expected to account for the largest share of the laboratory balances market, by product type, in 2018 Based on product type, the laboratory balances market is segmented into micro & ultra-micro balances, top loading/precision balances, analytical balances, portable/compact balances, moisture analyzers, and other balances. The analytical balances segment is expected to account for the largest share of the laboratory balances and scales market in 2018. The increasing adoption of analytical balances among biopharmaceutical industries, owing to its procedural benefits (such as portability, easy to operate, less weighing time, high durability, low cost, and high precision) is the major factor driving the growth of this market segment. The bench scales segment is expected to witness high growth rate in the laboratory scales market, by product type, in 2018 Based on product type, the laboratory scales market is segmented into bench scales, counting scales, compact scales, and other scales. The bench scales segment is expected to witness high growth rate in the laboratory scales market in 2018. The increasing adoption of laboratory scales among bio-pharmaceutical industry due to the procedural benefits offered by these instruments, such as flow-thru design ensures protection from liquids, touchless sensors, minimum stabilization time, ease of handling, and fast measurement time is the major factor driving the growth of this market segment. Pharmaceutical, cosmeceutical, and biotechnology product testing laboratories to account for the largest share of the global balances and scales market during the forecast period Based on end user, the laboratory balances and scales market is segmented into pharmaceutical, cosmeceutical, and biotechnology product testing laboratories; chemical and material testing laboratories; food and beverage testing laboratories; petroleum product testing laboratories; research laboratories & academic institutes, and other end users. The pharmaceutical, cosmeceutical, and biotechnology product testing laboratories segment is expected to account for the largest share during the forecast period. North America to dominate the laboratory balances and scales market during the forecast period The laboratory balances and scales market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The North America region is expected to account for the largest share of the global laboratory balances and scales market in 2018, and this trend is expected to continue during the forecast period. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=166668097 The major players operating in the laboratory balances and scales market are A&D Company, Ltd (Japan), Metler Toledo international, Inc. (US), Sartorius AG (Germany), Shimadzu Corporation (Japan), PCE Instruments (UK), Kern & Sohn GmbH (Germany), RADWAG Balances and Scales (Poland), Adam Equipment Co. (UK), Avery Weigh-Tronix, LLC (UK), Bonso Electronics International, Inc. (China), Essae Group (India), and Gram Precision S.L (Spain). Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.
The report Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605 The preimplantation genetic screening segment accounted for the largest share of the market in 2016 By type, the preimplantation genetic screening segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types. By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period The aneuploidy segment is expected to grow at the fastest CAGR. Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening. Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality). North America dominated the market in 2016 Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=605 As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others. Market growth is primarily driven by factors such as growing production of large molecules and biologics, technological advancements in nanofibers, growth in the generics market, and regulatory mandates for cleanrooms in pharmaceutical production. Other factors supporting market growth include an increase in R&D spending by biopharmaceutical companies to offer a strong biologics pipeline.
The global Pharmaceutical Filtration Market is poised to reach USD 22.71 Billion by 2021 from USD 13.73 Billion in 2016, at a CAGR of 10.6% from 2016 to 2021. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209343847 The global pharmaceutical filtration market is segmented on the basis of product, technique, application, scale of operation, and region. On the basis of product, the pharmaceutical filtration market is segmented into membrane filters, prefilters and depth media filters, cartridge & capsule filters, single-use systems, filter holders, filtration accessories, and other products. In 2016, the membrane filters segment accounted for the largest share of the market. This segment is also expected to register the highest CAGR during the forecast period. The key factor driving the growth of the membrane filters segment is the ease of installation in large and small manufacturing facilities owing to the availability of a variety of pore and surface types. Based on application, the final product-processing segment is expected to register the highest CAGR during the forecast period owing to the rapidly growing biologics and generic drug production coupled with the presence of stringent regulatory guidelines to maintain a clean and safe manufacturing environment. North America accounted for the largest share of the global pharmaceutical filtration market in 2016, followed by Europe. Stringent regulatory guidelines to provide safe drugs is encouraging the use of pharmaceutical filtration products and the presence of a large number of market players are propelling the growth of the North American pharmaceutical filtration market. The Asian region is expected to register the highest CAGR in the forecast period. Growing investments in the biopharmaceutical industry and the rise in contract research and manufacturing organizations in emerging Asian countries are the key factors driving the growth of the Asian market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=209343847 The pharmaceutical filtration market is dominated by established players such as Merck KGaA (Germany), GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), and Sartorius Stedim Biotech S.A. (France). The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.
The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period. Ask for PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092 Key Market Drivers:- 1 Growing Diabetic Population 2 Technological Advancements in Insulin Delivery Devices 3 Favorable Reimbursement Environment and Government Support in Selected Countries 4 Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices Market Segmentation:- Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016. This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region. By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure. Regional Analysis: - In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092 Top Key Players :- The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US). The global mycoplasma testing markets growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.
The global Mycoplasma Testing Market size is projected to reach USD 1,095 million by 2025 from USD 689 million in 2020, at a CAGR of 9.7%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856 Market Segmentation: - The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this markets largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the essential factors driving this market segments growth. Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segments growth. Regional Analysis:- The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global mycoplasma testing market. The large share can be attributed primarily to the growth in biotechnology and pharmaceutical industries, the high adoption rate of novel technologies, and the large number of life science research studies conducted in this region. Recent Developments
Top Key Players: - The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US) and Bionique Testing Laboratories, Inc. (US). |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |